We invite you to surf through the different sections of this page, where you can find all the important topics related to your participation at the ESMO Immuno-Oncology Congress 2021.
To get up to speed with your preparation for ESMO Immuno-Oncology Congress 2021, please download our Industry Guidelines below.
Other relevant information will be added to this page and don’t forget to bookmark us for easy access.
Third-party media activities
Media activities initiated by third parties during or in connection with ESMO Immuno-Oncology Congress 2021, including, but not limited to:
- Meetings such as press conferences, media briefings, educational sessions for media representatives, as well as
- PR activities, such as press releases, news, articles, interviews, etc.
are subject to the ESMO Policy on Third-Party Media Activities. This policy aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the conference.
Press events in or outside the congress centre but concomitant with/or during breaks of the scientific programme of ESMO Immuno-Oncology Congress 2021 are subject to ESMO Press Office approval. Please contact firstname.lastname@example.org
Official Italian agency for AIFA procedure
AIFA rules are mandatory only for Italian Pharmaceutical Companies that will attend a congress abroad.
Any pharmaceutical company supporting or participating in a congress, is subjected to an authorisation by AIFA (Italian Drug Agency), according to an Italian Government Decree (Decreto Legislativo 219/06 – art. 124). The request of authorisation must be submitted within 60 days before the starting date of the even.
ESMO advises pharmaceutical companies to contact the Official Agency:
AIM Group International – AIM Education S.r.l.
Contact: Crisitina Ghidoli
Via G. Ripamonti, 129
20141 Milan – Italy
Tel.: +39 02 56601 1
Fax.: +39 02 70048585